Tardy development of safe medicines for children; A Nordic network offers new platform to reduce this inequity.

Less than thirty percent of all marketed drugs worldwide have a paediatric licensing, and less than fifty percent of all marketed drugs are registered for children; in neonates less than ten percent (1, 2). This is not a fair situation since children should have the same right and access to tested medicines as adults. Even so, we see that off-label drugs are increasingly prescribed to children of all ages. This article is protected by copyright. All rights reserved.